Browse
Explore clinical trials and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
94760 trials found · Page 140 of 4738
-
Could a constipation drug slow cancer growth? new trial tests axelopran
Disease control Recruiting nowThe primary objective of this single arm, open label, phase II trial is to determine if axelopran use impacts cancer control in patients with advanced cancers of the lung, breast, pancreas, and prostate. The primary study period for assessing the primary aim is through day 43 (6 …
Phase: PHASE2 • Sponsor: HealthPartners Institute • Aim: Disease control
Last updated May 13, 2026 15:58 UTC
-
Your eyes could reveal hidden brain diseases, massive study hopes
Knowledge-focused Not yet recruitingThis project integrates multimodal eye data (CFP, OCT, OCTA) from 50,000 cases, brain MR data from 150,000 cases, and ICD diagnoses, medical orders, and test results from an eye-brain paired cohort of 8,000 cases to construct an eye-brain cross-modal mapping model and an eye-brai…
Sponsor: Beijing Friendship Hospital • Aim: Knowledge-focused
Last updated May 06, 2026 16:02 UTC
-
New hope for CML patients: drug combo aims to control cancer after first treatment fails
Disease control Not yet recruitingThis study is testing a new way to treat people with a type of blood cancer called chronic myeloid leukemia (CML) in chronic phase. This study is for the patients whose first treatment with a drug called a tyrosine kinase inhibitor (TKI; standard therapy) did not work well and r…
Phase: PHASE2 • Sponsor: University Health Network, Toronto • Aim: Disease control
Last updated May 15, 2026 11:57 UTC
-
New combo aims to keep advanced lung cancer in check
Disease control Not yet recruitingThe purpose of this study is to evaluate the efficacy and safety of lurbinectedin in combination with durvalumab for the treatment of participants with extensive stage small cell lung cancer (ES-SCLC) whose disease has not progressed after first line (1L) induction therapy.
Phase: PHASE2 • Sponsor: Jazz Pharmaceuticals • Aim: Disease control
Last updated May 14, 2026 12:03 UTC
-
Poop pills aim to end the vicious cycle of c. diff infections
Disease control Recruiting nowDouble blind RCT study of tretment of recurrent Clostridioides difficile infection by FMT capsules.
Phase: PHASE3 • Sponsor: Helsinki University Central Hospital • Aim: Disease control
Last updated May 15, 2026 11:53 UTC
-
New hope for hard-to-treat breast cancer: drug combo trial launches
Disease control Not yet recruitingThe study is being conducted to explore the reasonable dosage and evaluate the efficacy, safety and tolerability of HLX43 (Anti-PD-L1 ADC) as a monotherapy or in combination with immune checkpoint inhibitors in Subjects with locally advanced, recurrent or metastatic triple-negati…
Phase: PHASE2 • Sponsor: Shanghai Henlius Biotech • Aim: Disease control
Last updated May 14, 2026 12:05 UTC
-
Could cutting a nerve boost diabetes cure after Weight-Loss surgery?
Disease control Recruiting nowThis randomized, triple-blind clinical trial investigates whether adding truncal vagotomy to Roux-en-Y gastric bypass (RYGB) enhances remission of type 2 diabetes mellitus (T2DM) in patients with obesity. The study explores whether modulation of vagal signaling provides superior …
Phase: NA • Sponsor: University Research Institute for the Study of Genetic & Malignant Disorders in Childhood • Aim: Disease control
Last updated May 15, 2026 19:07 UTC
-
New study aims to find best artery treatment for young heart patients
Disease control Recruiting nowThe goal of this study is to investigate the equivalence in early and long-term efficacy between the two "Leave nothing behind strategies" (Drug-Coated Baloon \[DCB\] strategy with bail-out BioResorbable Scaffold \[BRS\] versus BRS strategy) of de-novo native coronary artery lesi…
Phase: NA • Sponsor: Ceric Sàrl • Aim: Disease control
Last updated May 11, 2026 20:40 UTC
-
New combo therapy aims to boost survival in returning head and neck cancer
Disease control Recruiting nowThis phase II trial tests the addition of chemotherapy, with carboplatin and paclitaxel, or chemo-immunotherapy, with carboplatin, paclitaxel and cemiplimab to standard salvage surgery followed by post operative radiation therapy and cisplatin for high risk patients, for the trea…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 30, 2026 15:50 UTC
-
Monthly IV drug aims to slash infection risk in blood cancer patients
Prevention Recruiting nowThe main goal of this study is to show that people with certain immune problems (from Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma) get fewer serious infections when they receive Gamunex C through an IV once every 4 weeks, along with their usual medical…
Phase: PHASE3 • Sponsor: Grifols Biologicals, LLC • Aim: Prevention
Last updated May 15, 2026 11:56 UTC
-
Heart attack prevention showdown: plaque imaging vs. blood flow tests
Disease control Recruiting now1. Study Purpose This study aims to compare clinical outcomes between two revascularization strategies in patients with high-risk coronary artery disease and 50-90% angiographic stenosis: a plaque burden and vulnerability-based revascularization strategy guided by intravascular i…
Phase: NA • Sponsor: Bon-Kwon Koo • Aim: Disease control
Last updated May 14, 2026 12:02 UTC
-
New hope for Tough-to-Treat leukemia: phase 3 trial pits rocbrutinib against pirtobrutinib
Disease control Recruiting nowThis is a Phase 3, randomized, open-label, multicenter study comparing rocbrutinib (LP-168) versus pirtobrutinib in adult participants with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have previously received a covalent Bruton…
Phase: PHASE3 • Sponsor: Newave Pharmaceutical Inc • Aim: Disease control
Last updated May 11, 2026 20:51 UTC
-
New PAH drug IKT-001 enters final testing phase
Disease control Recruiting nowThis is an adaptive, 2-part, randomized, multicenter, double-blind, placebo-controlled, parallel-group study designed to evaluate the efficacy and safety of IKT-001 in adult participants with WHO Group 1 PAH.
Phase: PHASE3 • Sponsor: Inhibikase Therapeutics • Aim: Disease control
Last updated May 15, 2026 11:57 UTC
-
Can a simple Fluid-and-Drug combo prevent kidney failure in septic shock?
Disease control Not yet recruitingSeptic shock is a life-threatening condition that can cause severe circulatory failure and damage to vital organs, including the kidneys. One of the most serious complications of septic shock is acute kidney injury (AKI), which is associated with increased morbidity and mortality…
Phase: NA • Sponsor: Universitas Sumatera Utara • Aim: Disease control
Last updated May 13, 2026 15:58 UTC
-
New drug shows promise in extending life for advanced bladder cancer patients
Disease control Recruiting nowResearchers are looking for new ways to treat locally advanced or metastatic urothelial cancer (UC). Current treatments for locally advanced or metastatic UC include chemotherapy, immunotherapy, and targeted therapy. Researchers want to know if giving sacituzumab tirumotecan (sa…
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated May 13, 2026 16:00 UTC
-
Brain tumor patients get virus injection in new safety trial
Disease control Recruiting nowThe goal of this clinical research study is to learn about the safety and effects of M032 given directly into the tumor in children and adults with DMG and who have received standard-of-care radiation therapy.
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 14, 2026 12:03 UTC
-
New combo therapy aims to boost brain recovery after severe stroke
Disease control Recruiting nowThis is an investigator-initiated phase III clinical trial employing a randomized, double-blind, placebo-controlled design. The primary objective of this study is to investigate the efficacy and safety of an interleukin-6 inhibitor (tocilizumab) combined with endovascular therapy…
Phase: PHASE3 • Sponsor: Capital Medical University • Aim: Disease control
Last updated May 15, 2026 11:54 UTC
-
New triple therapy shows promise for tough rectal cancer
Disease control Not yet recruitingAfter signing the informed consent form, patients who met the inclusion and exclusion criteria were given the full course of neoadjuvant treatment: short-term radiotherapy, followed by 6 consecutive cycles of disitamab vedotin, combined with sintilimab and capecitabine, and withi…
Phase: PHASE2 • Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology • Aim: Disease control
Last updated May 14, 2026 12:02 UTC
-
Could a diet boost Crohn's treatment in kids?
Disease control Recruiting nowChildren with Crohn's disease (CD), a type of Inflammatory Bowel Disease (IBD), often face serious health challenges, including poor growth, frequent hospital stays, and long-term medication use. Although biologic drugs like infliximab, an anti-TNFα (Tumor necrosis factor α) medi…
Phase: NA • Sponsor: University of British Columbia • Aim: Disease control
Last updated May 15, 2026 11:53 UTC
-
New shot aims to slash repeat stroke risk in patients with clogged arteries
Disease control Not yet recruitingThe Oris trial aims to evaluate whether the use of Ongericimab injection in patients with atherosclerotic ischemic cerebrovascular disease within 3 months of onset can reduce the risk of recurrent major cardiovascular events by achieving lower lipid-lowering target values (LDL-C …
Phase: PHASE3 • Sponsor: Beijing Tiantan Hospital • Aim: Disease control
Last updated May 15, 2026 18:53 UTC